That’s why we think supply challenges are going to get better, but it’s pretty broad-based. I can’t look at supply challenges and say it’s just this product or that product because it’s in packaging, it’s in resins. Almost everything that we’re dealing with has some form of supply challenges, like sterilization for instance, so I wouldn’t isolate the supply challenges to a product or product set. It’s just a broad-based pressure that we’re feeling. Outside of that, it’s around innovation that’s going to be building, and maybe you can talk to some of the things you’re excited about there.
Ivan Tornos: Yes, sure. Good to talk to you here today, Robbie. Innovation, as we discussed at JP Morgan earlier in the year, could be a three-hour conversation, so I’m going to try to keep it more or less succinct. But I will tell you, I truly believe today innovation is a key competitive advantage. Two data points right out of the gate that I mentioned, vitality index, the percentage of sales coming from new products has more than doubled over the last two years, and we expect the number to increase dramatically over the strategic horizon. Then the second part, we filed in 2022 the highest number of 510(k)s in the history of the company, and actually we had the largest number of approvals, public information, when it comes to the peer group.
Breaking down innovation into three or four buckets, when it comes to knees, I already mentioned Persona OsseoTi – that is the new cementless form factor, that device that we have here at Zimmer Biomet. The clinical data we have on that product is compelling. We believe it’s highly stable when it comes to the mechanical and biological fixation. It’s extremely versatile – you can all the way to the end of the surgery decide whether you want to go cemented or cementless. It does use the Persona technology, so it’s highly anatomic, you can customize the device to any kind of anatomy. We’ve got the broadest ranges. I’m excited with Persona Smart – we don’t talk much about it because we still are in the limited market trials, but I like where it’s going.
I like the opportunity that we have with Persona Smart, especially later in the year. When it comes to hips, in the prepared remarks, Bryan talked about HipInsight is the first and only mixed reality digital surgery platform for hip arthroplasty. This is making procedures faster. This is increasing accuracy in the actual procedure. When you come to the meeting in Vegas at the academy, I think you’ll be impressed. It effectively gives the surgeon X-ray vision over the anatomy of the patient, the instruments, the implants. You’re going to get more accuracy, faster procedures. It is going to be transformational. I like the momentum we have with both Rosa hips and knees. We have a strong portfolio when it comes to shoulder- let’s talk about Identity, the transformational launch that we did at the end of 2022.
That is followed by a cadence of launches on Glenoids, on Signature ONE planning – I could spend an hour on that, and then through organic and inorganic means, I think we have a best-in-class portfolio in sports med. This will be my three minute summary on a lot of things that are happening from an innovation standpoint, but I’ll close it by saying again, I do believe it’s a true competitive advantage for Zimmer Biomet.
Suketu Upadhyay: Yes, and Robbie, just back to your question around supply chain, our comments on Q4 and then 2023, we did see pressure in the fourth quarter around supply chain. I think you’ve heard us comment on that, and not inconsistent with what you’re hearing around the sector, we expect those challenges to continue into 2023. The commentary on Q4, just to provide a little color that we think that our group did a really nice job in navigating that. The situation continues to be dynamic into ’23, but our expectation is that we’re going to continue to navigate that really well.
